Expand FATE Menu
FATE MENU

FATE Stock Posts


Unusual Option Volume

FATE Fate Therapeutics2.59-0.25 (-8.8%)

Fate Therapeutics trades 2,598 contracts. The highest volume is in the 18-Jun-26 2 calls. News: Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting
Unusual Option Volume

FATE Fate Therapeutics2.11-0.14 (-6.2%)

Fate Therapeutics trades 3,031 contracts. The company has the following event: Bank of America Healthcare Conference 2026 on May 13, 2026. News: Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
Unusual Option Volume

FATE Fate Therapeutics2.28+0.48 (+26.7%)

Fate Therapeutics trades 2,302 contracts. The company has the following event: American Society of Gene and Cell Therapy (ASGCT) Annual Meeting on May 12, 2026. News: Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819
Unusual Option Volume

FATE Fate Therapeutics1.57+0.23 (+17.2%)

Fate Therapeutics trades 4,941 contracts. The company has the following event: EULAR 2025 on Jun 11, 2025.
Unusual Option Volume

FATE Fate Therapeutics2.47+0.45 (+22.3%)

Fate Therapeutics trades 2,212 contracts. The company has the following event: American College of Rheumatology (ACR) Convergence on Nov 18, 2024. News: Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence
Upcoming Earnings

FATE Fate Therapeutics3.82+0.12 (+3.2%)

Fate Therapeutics will report earnings after the market closes. View Calendar The market is expecting a ±11.8% move after earnings are reported. The average move for the past 4 quarters of earnings has been ±5.5%. View Expected Move (Conf Call: May 9 5:00 PM)
Market Data Delayed 15 Minutes